anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (e.g. human Factor VIIa) and a buffering agent; wherein the molar ratio of non-complexed calcium ions (Ca 2+ ) to the Factor VII polypeptide is lower than 0.5. The composition may further comprise a stabilizing agent (e.g. copper or magnesium ions, benzamidine, or guanidine), a non-ionic surfactant, a tonicity modifying agent, an antioxidant and a preservative. The composition is useful for treating a Factor VII-responsive syndrome, such as bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor XI deficiency, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand&#39;s disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a film-formable make-up cosmetic excellent in gloss.  &lt;P&gt;SOLUTION: A luminous pigment (1) and acetyl tributyl citrate (2) are incorporated in the film-formable cosmetic. The film-formable make-up cosmetic is suitably exemplified by a nail beantifying cosmetic. The luminous pigment is suitably exemplified by a rare earth-activated boron aluminate. More concretely, it is suitably illustrated by a luminous pigment activated by adding a small amount of europium oxide, dysprosium oxide, calcium oxide, and the like to a complex oxide such as strontium oxide, alumina, and boric acid anhydride. Examples of the film former in such a cosmetic include a nitrocellulose, collodion, a phthalate alkyd resin, an alkyl acrylate polymer, and an alkyl methacrylate polymer.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an antiviral agent having high antiviral activity against DNA-type viruses and RNA-type viruses such as herpes virus, influenza virus, human immunodeficiency virus and human coronavirus.  &lt;P&gt;SOLUTION: This agent contains an extract of Coccomyxa alga as an active component. More particularly, a polysaccharide fraction obtained from the extract of Coccomyxa alga is used as an active component. The extract is obtained by extracting the alga with hot water. The polysaccharide faction is obtained by eluting the extract of Coccomyxa alga with distilled water. More particularly, the polysaccharide fraction is obtained by eluting the extract of Coccomyxa alga with distilled water and then with an inorganic salt solution.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To produce a composition for the oral cavity, containing a specific polyglycerol monoester of a fatty acid as an active ingredient, having high safety, excellent feeling of use, e.g. foaming property, taste, etc., as well as good preservation stability with hardly any irritancy to mucous membranes. CONSTITUTION:A composition for the oral cavity containing a polyglycerol monoester of a fatty acid having &gt;=6 glycerol polymerization degree, 10-20 number of carbon atoms of the fatty acid, preferably 6-10 polymerization degree and 12-18C acyl group as the fatty acid as an active ingredient and preferably an N-acylamino acid or salt thereof together. In use, the composition is blended in a composition for the oral cavity, e.g. toothpaste, liquid dentifrice, etc. The amount of the blended active ingredient is preferably within the range of 0.5-3wt% and the amount of the blended N-acylamino acid, etc., is preferably within the range of 0.1-2wt%. The amount thereof used together with the polyglycerol monoester of the fatty acid which is the active ingredient is preferably 1-20pts.wt. based on 1-50pts.wt. active ingredient.
PURPOSE: To obtain the subject product consisting of a specific constitution, CO2 and an undissolvable compressed gas as propellants, capable of favorably retaining its spraying status to the last by making the best use of the advantages of both the CO2 as the dissolvable compressed gas and the undissolvable compressed gas. CONSTITUTION: (A) A stock solution, i.e., an aqueous solution or an alcoholic aqueous solution, containing an active ingredient or surfactant, (B) a carbonate or bicarbonate (pref. sodium carbonate or sodium bicarbonate) and (C) an organic or inorganic acid (pref. citric acid or hydrochloric acid), are put into an aerosol vessel followed by sealing and then pressurizing the vessel with an undissolvable compressed gas (e.g. N2 , helium), thus obtaining the objective product. Specifically, this product is obtained by the following procedure: either of the component B or C is incorporated, in advance, in the component A, and the other is then incorporated in the form of e.g. a water-soluble capsule in the component A. It is recommended that the undissolvable compressed gas be filled immediately after sealing the vessel.  It is preferable that the pressure of the gas inside the vessel is adjusted to 3.5-7.8kg/cm&lt;2&gt; at normal temperatures.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a technique which has a water-in-oil type emulsion form and enhances the transdermal absorption of a water-soluble active ingredient.  &lt;P&gt;SOLUTION: This external preparation for skins in a water-in-oil type emulsion form is characterized by comprising (1) an organic-modified clay mineral and (2) a hydroxylated phospholipid. It is preferable to contain a hydroxylated lecithin in a small sphere form in an aqueous phase. The small sphere is preferably liposome or vesicle. It is preferable that the liposome contains a water-soluble active ingredient in an inner aqueous phase. It is preferable that the vesicle contains an oil-soluble active ingredient.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Children (10 to 14 years) will be invited to come to a 1.5 hour laboratory assessment with a parent (most likely, mothers). We will gather parent-reported and children\&#39;s self-reported avoidant and engaged cognitive ER strategies, worded with third or first person, respectively. \&#34;Short form\&#34; versions will be used to reduce burden for children. The Emotion Regulation Questionnaire for Children and Adolescents provides a 6 item reappraisal scale and a 4 item expressive suppression scale. The Avoidance and Fusion Questionnaire for Youth - Short Form provides an 8-item measure of experiential avoidance. The extended version of the Children\&#39;s Response Styles Questionnaire provides a 5 item scale of problem-solving (also, \&#34;reflection\&#34;) and a 5 item scale of rumination (also, \&#34;brooding\&#34;). Mothers will complete the Children\&#39;s Responses to Feelings Checklist, which asks about these ER strategies in response to specific emotions, to examine specificity to threat (uncertainty/fear).

The investigators will also assess \&#34;in-vivo\&#34; use of cognitive ER strategies by using an ER strategy interview after children experience uncertainty via laboratory procedures. Children will watch a 2-minute clip from a live-action movie validated to elicit emotion in the domain of threat with school-aged children. The primary experimenter will interview the child about the cognitive ER strategies they used using open-ended questions with subsequent prompts to allow reports of multiple strategies. The primary experimenter will then ask closed-ended (yes/no) interview questions about each of the cognitive ER strategies of focus. Children will also complete two 5 minute tasks from the Laboratory Temperament Assessment Battery - Middle Childhood Version with established reliability and validity in the domain of threat. In the \&#34;Storytelling\&#34; task, the experimenter will instruct the child to stand and tell a story about the previous day in front of them and an unfamiliar research assistant (RA), enacting a series of standardized pauses and prompts until the child indicates they are finished. In the \&#34;Mask\&#34; episode, the child enters a room to see an adult RA wearing a mask resembling a disfigured face. The RA completes a standardized script of statements and pauses, finally taking off the mask and engaging the child in a friendly manner. The primary experimenter will repeat the ER strategy interview for the tasks. Auxiliary ER-relevant outcomes may supplement the primary focus on cognitive ER strategies. Behavioral tasks (Storytelling, Mask) can be coded for behavioral ER strategies (distraction, self-soothing, bids to experimenter). The investigators possess the necessary equipment and software for recording and analysis of children\&#39;s ECG and respiration to serve as physiological indicators of ER. As an additional indicator of family emotional environment, the child and mother will be prompted to converse about the activities in the lab.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; and R&lt;2&gt; are H, lower alkyl or lower alkenyl; R&lt;3&gt;-R&lt;5&gt; are H or lower alkyl; Y is H or lower acyl; m is 1 or 2; n is 0-2). EXAMPLE:3,3,5,5,8-Pentamethyl-1,7-nonadien-4-ol. USE:A perfumery component of perfumery composition. It has mossy top note accompanying green not like violet leaf, animalic and powderic perfume, and strong diffusibility and perfume-retainability, and harmonizes well with various other perfumery materials. It is useful also as a synthetic intermediate of the bicyclic alcohol of formula II and its ester with a lower aliphatic monocarboxylic acid. PREPARATION:The compound of formula I wherein Y is H can be prepared by reacting the oxygen-containing olefin of formula III (l is 0 or 1) with the organic magnesium compound of formula IV (X is halogen). The product can be converted another compound of formula I wherein Y is other than H by reacting with a lower aliphatic monocarboxylic acid.
An online game that promotes physical activity by visually representing the comparative biometric data of a group of people. The biometric data may be collected using a variety of biometric devices. Each individual in the group selects an avatar for use in representing the biometric data. The biometric data is transmitted to a server and displayed collectively on a computer screen. Each individual&#39;s avatar is displayed on the screen and animated according the biometric data. In an example embodiment in which avatars are fish that are displayed on a fish tank background and the biometric data is steps counted by a pedometer, avatars associated with individuals having a higher step count are positioned above avatars for individuals having a lower step count. Biometric data may be collected from biometric devices at various time intervals and the display updated to reflect the changes in biometric data.
Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise recombinant bacteria genetically modified to reduce the display of lipoteichoic acid on the cell surface. The methods of the invention comprise administering to a subject a recombinant bacterium modified to reduce the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacteria promotes a desired therapeutic response. The recombinant bacteria may be administered in a single dose or in a series of doses. The methods of the invention find use in the treatment or prevention of a variety of inflammatory conditions, including, for example, the treatment or prevention of inflammatory bowel disease, colitis, or crohn&#39;s disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To enable a dispensing pharmacy to record business processes from the acceptance of a prescription to administration to a patient.  &lt;P&gt;SOLUTION: This dispensing pharmacy system 100 uses a host computer 10 to create drug administration information for every prescription data input to a terminal, and stores the drug administration information in the host computer 10 for the prescription data generated. Identification information imparted to drug trays used in dispensing is obtained using IC tag readers 20a, 30a, 40a. The drug trays whose identification information has been obtained are imaged by means of imaging devices 20b, 40b. Their images taken and the identification information are stored in association with the drug administration information in the host computer 10.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (&#39;PAP&#39;) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.
PURPOSE: To obtain an inhibitor of superoxide production, containing a 1-naphthol derivative as an active ingredient, capable of manifesting excellent inhibiting actions on the O2 &lt;-&gt; production by human neutrophils, etc., and utilizable as a medicine such as an antiinflammatory agent or a therapeutic agent for autoimmune diseases. CONSTITUTION: This inhibitor contains 0.1-10wt.% compound of formula I [ring A is benzene, pyridine, thiazole ring, etc.; R&lt;1&gt; is H, a lower alkyl or an aromatic group; R&lt;2&gt; is a halogen or a lower alkyl; R&lt;3&gt; and R&lt;4&gt; are each H, a halogen, nitro, amino or a lower alkyl; (m) is 0-2; (n) is 1-4, etc.] as an active ingredient. The active ingredient can be prepared into an oral agent, a parenteral injection or a troche, a mucosal administering agent such as a suppository or a preparation for external use such as an ointment or an application agent. The daily dose thereof for an adult is 1-1000mg administered in divided 2-3 portions. The compound of formula I is new and can be obtained by reacting a compound of formula II with α-tetralone or its corresponding derivative in the presence of a base.
PROBLEM TO BE SOLVED: To provide a hair restoring means which imparts nutrients to the hair, improves the circulation of the blood of the head and is formed by making combination use of far IR rays. SOLUTION: The food consisting of the nucleic acid-contg. material obtd. by fermentation of a calcium compd. consisting essentially of calcium carbonate and vegetable protein and outfits consisting of fibers kneaded with far IR radiative particulates are used in combination in this hair restoring method. Reef coral formed by weathering is preferably used as natural coral and soybean protein is used as the vegetable protein. In addition, the far IR radiative particulates which have a grain size of &lt;=0.5 micron and radiate growing rays of a wavelength of 5 to 20 microns are used as the far IR radiative particulates.
1329242 Fluoro-polymer compositions UNILEVER Ltd 21 Oct 1970 [24 Oct 1969] 52301/69 Heading C3P [Also in Division A5] A vinyl polymer derived from a fluorine-containing monomer of the formula (wherein Y is a partially or wholly fluorinated C 1-11  alkyl group, Y&lt;SP&gt;1&lt;/SP&gt; and Y&lt;SP&gt;11&lt;/SP&gt; are each H or partially or wholly fluorinated C 1-11  alkyl groups and R&lt;SP&gt;2&lt;/SP&gt; is H or CH 3 ) is used to treat wet hair to reduce the time required for the drying thereof. The polymer may be applied to the hair from a hair cosmetic preparation or from an aqueous latex emulsion. The preparations may contain the polymer in an amount of from 0À0001 to 6% by weight and the emulsion may contain it in an amount of from 0À0001 to 0À02% by weight. The vinyl polymers are formed by free radical catalysed polymerization of terminally unsaturated monomers, and they can be homopolymers or copolymers of the monomers with other monomers which contain an ethylenic linkage, e.g. conjugated dienes such as butadiene and chloroprene, and alkyl, aminoalkyl or vinyl esters of acrylic and methacrylic acids. It is preferred that the vinyl polymer is also derived from N,N-diethylaminoethyl methacrylate or butyl methacrylate. The polymers may also be terpolymers or quaterpolymers of the fluorinated monomers and other monomers. In an example 1H,1H-perfluorobutyl methacrylate is polymerized in aqueous emulsion using N,N-dimethyloctadecylamine acetate as surfactant and 2,2&lt;SP&gt;1&lt;/SP&gt;-azobisisobutyramidine dihydrochloride as initiator. Other polymers are also described and other methods of preparation referred to. A shampoo solution containing monoethanolamine lauryl sulphate (10%) and 0À003-0À3% by weight of the vinyl polymer solids is used to demonstrate the reduction of drying time of wet hair to which the shampoo has been applied as compared with the use of a shampoo containing no polymer or a known fluoropolymer Zepel B (Zepel is a Registered Trade Mark). Other shampoo compositions containing other detergents are also described. Specification 1,268,636 is referred to.
PROBLEM TO BE SOLVED: To obtain a new compound useful for preventing and treating diseases caused by cell proliferation of smooth muscle such as blood vessel restenosis and arteriosclerotic diseases, having a specific structure, capable of suppressing the proliferation of smooth muscle cells. SOLUTION: This new compound is shown by formula I (R&lt;1&gt; is H, a 2-6C alkyl, etc.; R&lt;2&gt; is H, a 1-6C alkyl, etc.; R&lt;3&gt; is H, a 1-6C alkyl, etc.; R&lt;4&gt; and R&lt;5&gt; are each H, a 1-6C alkyl, etc.; X is O or S) such as N-propyl-N&#39;-(1-benzyl-4- ethoxycarbonylpyrazol-3-yl)urea. 3-Ethoxy-2-cyanopropenioc acid of formula II is subjected to a ring formation reaction with a hydrazine of the formula R&lt;1&gt; -NH-NH2 in a lower alcohol-based solvent at a room temperature to the heating temperature with reflex to give an intermediate compound of formula III. Then the compound of formula III is reacted with an alkylating agent in the presence of a base to give a 1-substituted-3-amino-4-alkoxycarbonylpyrazole type compound of formula IV. The compound of formula IV is reacted with an isocyanate of the formula R&lt;4&gt; -N=C=X to give the objective pyrazole derivative of formula I.
PURPOSE:To obtain the titled compound of high purity by extremely simple operation, by hemolyzing erythrocytes, controlling pH to precipitate and remove hemoglobin, adding a metal salt to the formed supernatant liquid and further controlling the pH to precipitate and remove the residual proteins. CONSTITUTION:Water is added to hemolyze erythrocytes and the resultant hemolyzed solution is then treated at &lt;=6.5 pH to denature hemoglobin. The pH of the above-mentioned hemolyzed solution is then adjusted to 7-8 to precipitate hemoglobin. A metal salt is added to the supernatant liquid free of the above-mentioned precipitates and the pH is further adjusted to 6-9 to remove unnecessary proteins contained in the supernatant liquid as precipitates. Thereby the aimed compound of high purity is obtained. A salt of a transition metal, e.g. Cu, Fe or Mn, or amphoteric metal, e.g. Al or Zn, capable of forming chelate bonds to proteins, dissolving in an acidic solution and precipitating as hydroxides under neutral and alkaline condition is used as the above- mentioned metal salt.
A method for reporting a user&#39;s emergency condition by sending an emergency help request message in a TCP/IP format to an emergency service center (ESC). The help request message may be sent over the Internet to advantageously harness the data transmission resources provided by the Internet. A support service provider may commercially provide such an emergency reporting service to a group of subscribers. The service provider may receive emergency requests from the subscribers and may send those requests over the Internet to the emergency service center. The service provider may also convert any non-TCP/IP message received from the subscriber into a TCP/IP message prior to sending the message to the ESC. A per-usage fee or a flat subscription fee may be charged by the service provider to allow users to report emergency conditions over the Internet. The support service provider thus coordinates the emergency help on behalf of the user. Internet-based emergency message delivery may be useful in many situations, for example, when the person in need of help is mute, disabled or in a situation that prevents the person from orally requesting emergency help from the ESC.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for improving bitter taste and harsh taste without impairing bioutility, in a calcium L-threonate-containing oral administration preparation.  &lt;P&gt;SOLUTION: This oral administration composition containing the calcium L-threonate is characterized by further containing a sugar alcohol and guar gum and/or gelatin. The sugar alcohol is preferably selected from sorbitol, mannitol, erythritol, threotol, maltitol, xylitol, lactitol, and trehalose. The total content of the sugar alcohol is preferably 10 to 50 mass % based on the total amount of the composition. It is preferable that both the guar gum and the gelatin are contained.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Method and apparatus for providing authorized access to medical information concerning an individual while preserving the confidentiality of, and preventing unauthorized access to, such information. A computer database receives and stores the individual&#39;s medical information, after the individual is tested to establish this information and the date on which such information was most recently obtained. The computer database does not contain the individual&#39;s name, address or any other similar information by which the individual can be identified. The individual is given an identification card containing a photograph or holographic image of the individual and containing a confidential first identification number that is unique for the individual, where both the image and the first identification number are visually perceptible and cannot be altered on the card without detection of such alteration. The individual is also given a confidential second identification number that is not contained on the card and need not be unique for that individual. The computer database can be accessed telephonically, and the individual&#39;s medical information, or a portion thereof, can be read only by an inquiror, if the inquiror or the individual first provides the individual&#39;s first and second identification numbers. The inquiror can use the image and first identification number on the individual&#39;s card to confirm the identity of that individual but need not be told the individual&#39;s second identification number. After inquiror establishes the identity of the individual, the inquiror, with the assistance of the individual, can obtain a telephonic readout of the individual&#39;s medical information.